Imatinib Stada (Imatinib)

Imatinib is indicated for malignancies driven by BCR‑ABL, c‑KIT or PDGFR tyrosine‑kinase signaling.

• Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and improves long‑term survival.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): induces remission by targeting BCR‑ABL‑positive blasts.
• Gastrointestinal stromal tumor (GIST): inhibits c‑KIT driven tumor growth and delays disease progression.

• Imatinib binds competitively to the ATP‑binding pocket of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, stabilising them in an inactive conformation. This blocks downstream signaling pathways that drive cell proliferation, survival and angiogenesis, leading to apoptosis of malignant cells that depend on these kinases.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Edema: peripheral swelling, often of the ankles.
• Muscle cramps or pain: especially in the lower limbs.
• Fatigue: generalized tiredness.
• Diarrhea: loose stools, usually self‑limiting.
• Rash: mild skin erythema.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or hepatitis.
• Severe neutropenia or thrombocytopenia: increased infection or bleeding risk.
• Cardiac failure: reduced left‑ventricular ejection fraction.
• Pulmonary hypertension: shortness of breath and elevated pulmonary arterial pressure.

Careful monitoring and patient education are essential when using Imatinib.

• Dose adjustment in hepatic impairment: reduce dose based on liver function test results.
• Monitor blood counts regularly: watch for neutropenia, anemia and thrombocytopenia.
• Assess cardiac function: patients with pre‑existing heart disease need baseline and periodic ECGs.
• Avoid in patients with known hypersensitivity to imatinib or its excipients.
• Review concomitant CYP3A4 inhibitors or inducers: adjust therapy as needed.
• Store at below 25 °C: keep in the original container, protect from moisture and light.

Imatinib may interact with several co‑administered medicines, requiring clinical vigilance.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase imatinib plasma levels and toxicity.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy by lowering drug concentrations.
• Antacids containing aluminum or magnesium: can impair absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

• Warfarin: imatinib can enhance anticoagulant effect; monitor INR.
• Diuretics (e.g., furosemide): may increase risk of fluid retention.
• QT‑prolonging agents (e.g., sotalol): monitor cardiac rhythm for arrhythmias.